Combo immunotherapy ups survival in advanced liver cancer
(HealthDay)—STRIDE (Single tremelimumab Regular Interval durvalumab) is proposed as first-line therapy for unresectable hepatocellular carcinoma (uHCC), according to a study presented at the annual American Society of Clinical ...
Jan 24, 2022
0
46